$OURA

Smart ring maker Oura, shareholders look to raise up to $2.2 billion in US IPO

Oura, a maker of smart rings, plans to raise up to $2.2 billion in a US IPO, selling 50 million shares at $40-$44 each. Eli Lilly and Dragoneer may invest $100M and $300M, respectively. The company will list on Nasdaq as 'OURA'.

Original reporting
Published Sep 21, 2026, 11:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 11:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefIPO
Primary signal
$OURA
Bullish
high confidence
Mentioned
$OURA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OURABullishHigh
01

Why it matters

The filing signals a major capital infusion and expands the public market's exposure to digital health wearables.

02

Market read

First‑time public offering of a fast‑growing health‑tech firm, likely to attract both retail and institutional interest.

03

What to watch

Regulatory scrutiny of health data privacy and competition from larger wearables brands.

Relevance 8/10Novelty 8/10Timing: today

Background

Oura's smart ring tracks health metrics; the company seeks to capitalize on growing consumer health monitoring trends.

Company-level read

Ticker impact

$OURABullishHigh confidence
Context

Oura filed to raise up to $2.2 billion in a US IPO, offering 50 million shares at $40‑44 each and will list on Nasdaq as OURA.

Expected impact

Expect near‑term price swing of ±5‑10% as market digests valuation and demand from anchor investors.

Evidence & confidence

Large raise size, anchor interest from Eli Lilly and Dragoneer, and Nasdaq listing create strong buying pressure, but pricing range leaves upside/downside risk.

Market effects

Adds a high‑growth consumer‑health tech player to the wearables sector, potentially lifting peers.

Boosts US IPO pipeline confidence amid market volatility.

Highlights continued investor appetite for health‑monitoring devices worldwide.

Counterpoint

The IPO may be over‑priced; demand could wane if market volatility persists.

Key entities

  • Oura

    Smart ring maker filing for US IPO.

  • Eli Lilly

    Potential anchor investor committing up to $100 million.

  • Dragoneer

    Potential anchor investor committing up to $300 million.

Related articles

$COINMedAI 8/10

Coinbase Opens IPO Access — Oura Is First, But There's a Catch

Coinbase launched a new service allowing eligible U.S. retail customers to request allocations in IPOs, starting with Oura's $2.2B IPO. Oura plans to sell 13.5M shares at $40-$44 each, with a fully diluted valuation of about $15.62B. Coinbase's IPO access prioritizes long-term investors, discouraging early selling.

$OURAHighAI 9/10

Smart ring maker Oura targets $2.2 billion in US listing

Oura Inc, a smart ring maker, aims to raise $2.2B in a US IPO, offering 50M shares at $40-$44 each. The company could be valued at $14.1B-$15B. Oura reported a $924.3M net loss on $1.21B revenue for the nine months ended June 30. The IPO is expected to price on September 29, with shares trading on Nasdaq under ticker OURA.

$COINHigh

Coinbase IPO News: US Retail Access Opens, With Oura Up First

Coinbase launched a feature allowing eligible US retail customers to request IPO shares, starting with Oura. Oura plans to offer 13.5M shares priced between $40 and $44, listing on Nasdaq as OURA. Coinbase's stock (COIN) rose 3.5% to $201.05 on the news, with a market cap of $53.04B. Oura's IPO is expected to price this week.

$OURAHighAI 9/10

Oura smart ring IPO roadshow launches, targets $2.2 billion

Oura Health launched its IPO, aiming to raise $2.2B by selling 50M shares at $40-$44 each, targeting a $15.62B valuation. Trading under 'OURA' on Nasdaq, it sold 3.6M rings in the past year with $1.21B revenue. Eli Lilly and Dragoneer may invest $100M and $300M respectively. The company faces a lawsuit over sleep tracking accuracy claims.